CANCER EDITION: PHARMA’S CORPORATE REPUTATION IN 2021
The patient’s perspective—Cancer edition
The views of 520 cancer patient groups
Contact: Alex Wyke Tel. : +44-(0)-7960-855-019
Email: [email protected]
London, May 31, 2022
PatientView is today releasing the results of its latest Corporate Reputation of Pharma Survey – Cancer Edition, now in its 9th year and two years into the Covid-19 pandemic. Between November 2021 and February 2022, the survey collected the opinions of 520 cancer patient groups on the performance of the pharmaceutical industry in 2021.
Patient groups responding to the Corporate Reputation of Pharma survey are uniquely positioned to comment on the performance of the pharmaceutical industry during the pandemic. Patient groups not only understand patient perceptions, but are also the only health actors to network with all other actors in the health system.
Keep reading for more details on:
} How PatientView measures the reputation of the pharmaceutical company from the patient’s point of view;
}The main results of the 2021 survey, from the perspective of cancer patient groups;
}Companies included in the 2021 Cancer Analysis; and
}Profiles of cancer patient groups responding in 2021.
Content and tables can be downloaded here
PatientView’s annual online Corporate Reputation of Pharma survey measures various aspects of the performance of the pharmaceutical industry, all from the perspective of the patient and the patient group. The survey questions to responding patient groups fall into two areas:
(1) The performance of the the pharmaceutical industry as a whole, relative to other healthcare industries, ―and for various activities important to patients.
(2) The performance of individual pharmaceutical companies (30 in total in the cancer edition of the 2021 survey results). Companies are rated by patient respondent groups for their performance across nine corporate reputation indicators. A new indicator, the 10th, has been added to the previous year’s survey (that of 2020), focusing on companies’ support for patients during the Covid-19 pandemic. This indicator was retained in the 2021 survey [see chart below].
The nine indicators that measure pharmaceutical company reputation, from a patient perspective, plus a 10th indicator, examining the pharmaceutical industry’s patient support during the Covid-19 pandemic
Responding cancer patient groups are asked to nominate the three companies they believe are “best” for each of the company reputation indicators.
The 30 companies included in the oncology component of the 2021 ‘Corporate Reputation of Pharma’ analyses:
AbbVie I Amgen I Astellas Pharma I AstraZeneca I Bayer I Boehringer Ingelheim I Bristol Myers Squibb I Daiichi Sankyo I Dr Reddy’s I Eisai I Eli Lilly I Gilead Sciences I GSK I Ipsen I Janssen I Menarini I Merck & Co/MSD I Merck KGaA/EMD Serono I Mylan I Novartis I Otsuka I Pfizer I Pierre Fabre I Roche/Genentech I Sandoz I Sanofi I Servier I Sun Pharma I Takeda I Teva
The number of responding cancer patient groups who know of or work with the companies listed above [https://bit.ly/3lF1Qa0].
Click here to learn more about PatientView’s methodology for the 2021 Corporate Reputation of Pharma (published in 2022).
SUMMARY OF RESULTS
The 520 cancer patient groups who responded to the 2021 ‘Corporate Reputation’ survey rated the pharmaceutical industry more favorably for corporate reputation than their predecessors in all previous years . 67% of cancer patient groups surveyed in 2021 said the industry had an “Excellent” or “Good” corporate reputation, compared to 57% saying the same in 2020. Although many cancer patients suffered indirect consequences of the pandemic, the sentiment of cancer patient groups towards the industry, and its achievements, particularly in relation to the Covid-19 pandemic, remained positive in 2020 and 2021. 81% of 520 responding cancer patient groups in 2021 thought the pharmaceutical industry was ‘very effective’ or ‘effective’ in supporting patients during the Covid-19 pandemic– higher than equivalent figures received from 2021 respondent patient groups from other therapeutic areas.
However, cancer patient groups surveyed in 2021 are not uniform in their views on the reputation of the pharmaceutical industry. Lung cancer patient groups were the most positive about the pharmaceutical industry in 2021; blood, digestive and rare cancer patient groups were the least positive. So why the difference?
Figure 2: The reputation of pharmaceutical companies, 2021
Percentage of Responding Cancer Patient Groups Rating “Excellent” or “Good”
The cancer patient groups that shaped the reputation of the pharmaceutical industry in 2021 highlighted many areas of unmet patient needs in cancer R&D, including:
}Patient access to cancer drugs.
}The need to focus on the quality of life of cancer patients.
}The need for real-world evidence (RWE) on the tolerability and side effects of cancer drugs.
}The need for cancer R&D to consider broader patient populations.
COMPANY RANKING – ALL CANCERS
}The top three pharmaceutical companies out of 30 companies, ranked for overall business reputation in 2021, as assessed by respondent cancer patient groups familiar with the business:
Pfizer1st | Roche/Genentech2nd | Novartis3rd.
}The top three pharmaceutical companies out of 26 companiesranked for their overall corporate reputation in 2021, as assessed by responding cancer patient groups working with the company:
Pfizer1st | Roche/Genentech2nd | Janssen3rd.
}The companies making the most progress in the rankings, from 2020 to 2021, as assessed by respondent cancer patient groups familiar with the company, can be viewed in the table below.
Chart 3: Companies with the largest increases from 2020 to 2021, as assessed by respondent cancer patient groups familiar with the company
Climbs listed from top to bottom, left to right
THE VIEWS OF 84 LEUKEMIA PATIENT GROUPS
Janssen1st | AbbVie2nd | Pfizer3rd
THE VIEWS OF 92 BREAST/FEMALE CANCER PATIENT GROUPS
Pfizer1st | Roche/Genentech2nd | Novartis3rd
THE VIEWS OF 28 LUNG CANCER PATIENT GROUPS
Roche/Genentech1st | Takeda2nd | Pfizer3rd
THE VIEWS OF 42 PROSTATE-/CANCER-MAN
Janssen= 1st | Pfizer, = 1st | Astellas3rd
“Listen to expert patient advice. Ensure that their medicines actually reach the market, instead of demanding prices that are impossible for certain countries. Engage with HTAs and payers, instead of sitting on their meds. »
―National Blood Cancer Patient Group, UK
PROFILE OF RESPONDENTS
The 520 responding cancer patient groups of 2021 specializing in 24 different kinds cancer [see chart below].
Chart 4: Oncology specialties of responding cancer patient groups, 2021
Figure 5: Geographic location of responding cancer patient groups, 2021
patiententView would like to thank the 520 cancer patient groups who volunteered their time to complete the 2021 Corporate Reputation of Pharma survey (published in 2022).
For more information on this report, please use the contact details at the top of the press release.